Immunotherapy for breast cancer: past, present, and future

Alison Spellman, Shou Ching Tang

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

Immunotherapy has shown promise in many solid tumors including melanoma and non-small cell lung cancer with an evolving role in breast cancer. Immunotherapy encompasses a wide range of therapies including immune checkpoint inhibition, monoclonal antibodies, bispecific antibodies, vaccinations, antibody-drug conjugates, and identifying other emerging interventions targeting the tumor microenvironment. Increasing efficacy of these treatments in breast cancer patients requires identification of better biomarkers to guide patient selection; recognizing when to initiate these therapies in multi-modality treatment plans; establishing novel assays to monitor immune-mediated responses; and creating combined systemic therapy options incorporating conventional treatments such as chemotherapy and endocrine therapy. This review will focus on the current role and future directions of many of these immunotherapies in breast cancer, as well as highlighting clinical trials that are investigating several of these active issues.

Original languageEnglish (US)
Pages (from-to)525-546
Number of pages22
JournalCancer and Metastasis Reviews
Volume35
Issue number4
DOIs
StatePublished - Dec 1 2016

Keywords

  • Biomarkers
  • Breast cancer
  • Checkpoint inhibitor
  • Clinical trials
  • Immunotherapy
  • Review

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Immunotherapy for breast cancer: past, present, and future'. Together they form a unique fingerprint.

  • Cite this